文献速递肝病

实验性硬化性胆管炎中肝脏调节性T细胞功能障碍与IL-12信号相关

Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling.
PubMed 文献 · J Hepatol · 2016-12-10

在Mdr2-/-和DDC小鼠胆管炎模型中,反复注射IL-2/IL-2Ab复合物使肝脏Treg扩增5倍并定位于炎症门管区,但胆管炎严重程度未减轻。肝脏Treg的Foxp3表达和抑制功能低于脾脏Treg,与IL-12受体上调增强IL-12信号有关;IL-12rb2-/-小鼠能维持肝脏Treg功能,作者提出中和IL-12应作为靶向Treg治疗策略的一部分。

要点

  • IL-2/IL-2Ab复合物使胆管炎小鼠肝脏Treg扩增5倍,但未减轻胆管炎严重程度。
  • 肝脏Treg较脾脏Treg的Foxp3表达和抑制功能降低,与IL-12受体上调相关。
  • IL-12rb2-/-小鼠能维持肝脏Treg功能,作者提出中和IL-12应作为靶向Treg治疗策略的一部分。

核心结论

  • 肝脏Treg在体内扩增后未能改善胆管炎病程,这与肝脏IL-12对Treg的作用相关;作者提出中和IL-12应作为靶向Treg治疗硬化性胆管炎策略的一部分。

研究设计与样本

  • 在胆管炎小鼠模型(Mdr2-/-、DDC)及作为对照的结肠炎模型(DSS)中,通过反复注射IL-2/IL-2Ab复合物扩增Treg,并分析分离的肝脏与脾脏Treg的体外抑制能力和基因表达。

主要发现

  • 体内扩增使肝脏Treg增加5倍,并定位于炎症门管区;Treg扩增伴随肝脏淋巴细胞促炎IL-17减少和抗炎IL-10增加,但胆管炎严重程度未减轻。
  • DSS诱导的结肠炎可通过Treg扩增得到改善,提示肝内Treg功能选择性降低。
  • 肝脏Treg较脾脏Treg表现为Foxp3表达降低和抑制能力降低。
  • 肝脏Treg功能障碍与IL-12受体上调导致的IL-12信号增强相关;IL-12rb2-/-小鼠能维持肝脏Treg功能。

临床怎么用

  • 作者认为,中和IL-12应作为靶向Treg治疗硬化性胆管炎策略的一部分,以提高Treg为基础治疗肝脏疾病的疗效。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Reduced numbers of regulatory T cells (Treg) have been reported in patients with primary sclerosing cholangitis (PSC); therefore, Treg expansion might serve as a therapeutic approach. Here, we explored whether treatment with IL-2/IL-2 monoclonal antibody complex (IL-2/IL-2Ab complex) could provide in vivo Treg expansion and treatment of experimental sclerosing cholangitis. METHODS: Treg were expanded by repeated injection of IL-2/IL-2Ab complex in mouse models of cholangitis (Mdr2-/-, DDC) or colitis (dextran sulfate sodium [DSS]) as control. In vitro suppressive capacity and gene expression were analyzed in isolated hepatic and splenic Treg. RESULTS: In vivo expansion resulted in a 5-fold increase in hepatic Treg, which localized within the inflamed portal tracts. However, although Treg expansion was associated with reduced pro-inflammatory IL-17 and increased anti-inflammatory IL-10 production by hepatic lymphocytes, the severity of cholangitis was not reduced. In contrast, DSS-induced colitis could be improved by Treg expansion, suggesting a selectively reduced functionality of intrahepatic Treg. Indeed, hepatic Treg manifested reduced Foxp3 expression and reduced suppressive capacity compared to splenic Treg. Hepatic Treg dysfunction could be linked to increased IL-12 signaling due to an upregulation of the IL-12 receptor. Accordingly, IL-12 receptor beta 2 knockout mice (IL-12rb2-/-) were able to maintain hepatic Treg functionality. CONCLUSIONS: Hepatic Treg expanded in vivo failed to improve the course of cholangitis, which was related to the effects of hepatic IL-12 on Treg. Therefore, neutralization of IL-12 should be considered as part of treatment strategies targeting Treg in sclerosing cholangitis. LAY SUMMARY: Primary sclerosing cholangitis (PSC) is associated with a paucity of regulatory T cells (Treg) that have a particular ability to control immune responses; therefore, in vivo expansion of Treg might serve as a treatment of cholangitis. However, in a mouse model of PSC, we show that Treg enrichment in the liver was not sufficient to provide effective control of cholangitis, as the suppressive functionality of hepatic Treg was significantly limited by IL-12 signals. Thus, neutralization of IL-12 should be considered as part of treatment strategies to improve the efficacy of Treg-based treatments for liver diseases. Data accession number: GSE 87898.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Schwinge D, von Haxthausen F, Quaas A, et al. Dysfunction of hepatic regulatory T cells in experimental sclerosing cholangitis is related to IL-12 signaling. J Hepatol. 2016. PMID: 27965154. doi:10.1016/j.jhep.2016.12.001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。